Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: firstname.lastname@example.org
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Olympic travelers face tiny risk of Zika: US study
26 Jul 2016 at 12:52am
Under a worst-case scenario, just three to 37 of the up to 500,000 people expected to go to Rio de Janeiro for the games, which start next month, could be expected to come down with Zika, said the report by the Yale University School of Public Health. "The possibility that travelers returning from the Olympics may spread Zika has become a polemic issue that has led to athletes dropping out of the event, and without evidence, undue stigmatization of Brazil," said study co-author Albert Ko, chair of the Department of Epidemiology of Microbial Diseases at Yale. The research, published in the Annals of Internal Medicine, is based on a mathematical model that accounted for a series of factors, including recent Zika transmission in Rio de Janeiro, seasonal conditions and travel patterns.
Australian PM orders inquiry after teenage prisoners teargassed, stripped naked
26 Jul 2016 at 12:41am
By Matt Siegel and Tom Westbrook SYDNEY (Reuters) - Australian Prime Minister Malcolm Turnbull on Tuesday ordered an inquiry into the treatment of children in detention after the airing of video showing prison guards teargassing teenage inmates and strapping a half-naked, hooded-boy to a chair. Footage of the abuse of six aboriginal boys in a juvenile detention center sparked renewed criticism of Australia's treatment of Aborigines and their high imprisonment rate. The Australian Broadcasting Corporation (ABC) aired CCTV footage late Monday of boys in a Northern Territory juvenile detention center also being stripped naked, thrown by the neck into a cell, and held for long periods in solitary confinement.
Knife attacker in Japan kills 19 in their sleep at disabled center
26 Jul 2016 at 12:24am
By Elaine Lies and Kwiyeon Ha SAGAMIHARA, Japan (Reuters) - A knife-wielding man broke into a facility for the disabled in a small town near Tokyo early on Tuesday and killed 19 patients as they slept, authorities said, Japan's worst mass killing in decades. At least 25 other residents were wounded in the attack at the Tsukui Yamayuri-En facility in Sagamihara town, about 25 miles (40 km) southwest of Tokyo. "This is a very heart-wrenching and shocking incident in which many innocent people became victims," Chief Cabinet Secretary Yoshihide Suga told a regular news conference in Tokyo.
Shock as peaceful Japanese town wakes to 'unthinkable' disabled center horror
25 Jul 2016 at 11:12pm
By Elaine Lies and Kwiyeon Ha SAGAMIHARA, Japan (Reuters) - Shock and bewilderment gripped neighbors of a disabled center in a town near Tokyo on Tuesday after a man stabbed and killed 19 residents in their sleep and wounded dozens more in Japan's worst mass killing in decades. "This kind of thing doesn't happen in Japan. It's unthinkable it happened so close to me," said Masae Mizoguchi, a 78-year-old retiree who lives up the hill from the Tsukui Yamayuri En (Tsukui Lily Garden) facility.
Early menopause may speed up aging in women: study
25 Jul 2016 at 10:24pm
Women who enter menopause early may age faster than women in whom menopause arrives later, said a study Monday that could help pinpoint women at highest risk of age-related diseases. The findings could settle a long-standing debate, said Steve Horvath, a professor of human genetics and biostatistics at the David Geffen School of Medicine at the University of California, Los Angeles. "For decades, scientists have disagreed over whether menopause causes aging or aging causes menopause," said Horvath, senior author of the study in the Proceedings of the National Academy of Sciences.
Japan knifing suspect had said he was willing to kill disabled-official
25 Jul 2016 at 10:11pm
The suspect in a fatal stabbing spree in Japan on Tuesday had been hospitalized early this year after expressing a willingness to kill disabled people if the government approved, a city official said. Police in the town of Tsukui near Tokyo contacted the suspect, Satoshi Uematsu, and he was involuntarily committed to hospital on Feb. 19 after he had tried to present a letter to the speaker of the lower house of Japan's parliament, said an official from nearby Sagamihara city who declined to be named. Nineteen people were stabbed and killed in their sleep and at least 25 wounded at a facility for the disabled in Sagamihara in the early hours of Tuesday.
Japanese government spokesman told 19 dead after knife attack
25 Jul 2016 at 7:59pm
TOKYO (Reuters) - Japan's top government spokesman said on Tuesday he had been told that 19 people were dead after an attack by a knife-wielding man at a facility for the disabled in central Japan. Chief Cabinet Secretary Yoshihide Suga also told a news conference that police had not obtained any information to suggest there was a link between the attack and Islamist extremism. (Reporting by Kaori Kaneko; Editing by Paul Tait)
China's condom policies to prevent HIV fail to protect sex workers: research
25 Jul 2016 at 5:03pm
By Alisa Tang BANGKOK (Thomson Reuters Foundation) - Chinese police cracking down on sex workers routinely look for condoms as evidence of illegal activity, hindering efforts to prevent the spread of HIV among sex workers, one of the biggest at-risk groups in the country, experts said. China, with a population of about 1.4 billion, has a relatively low HIV prevalence rate, with around half a million reported cases of people living with HIV or AIDS by the end of 2014, according to a government report published last year. Up to 92 percent of the 104,000 cases diagnosed in 2014 resulted from sexual contact, according to research commissioned by Asia Catalyst, which promotes the right to health of marginalized groups in the region.
100-year global study finds world's tallest are Dutch, Latvians
25 Jul 2016 at 4:13pm
By Kate Kelland LONDON (Reuters) - Dutch men and Latvian women are the planet's tallest people but Iranian men and South Korean women have grown the fastest in the last century, according to the largest ever study of height around the world. Americans, once among the world's tallest people, have dropped from having men and women at 3rd and 4th in the global height rankings a 100 years earlier, to placing 37th and 42nd respectively in 2014. The research, led by scientists at Imperial College London and published in the journal eLife, also found some nations have stopped growing over the past 30 to 40 years, despite having spurts at the start of the century studied.
Nineteen feared dead after knife attack in Japan: media reports
25 Jul 2016 at 4:07pm
By William Mallard TOKYO (Reuters) - Nineteen people were feared dead and 45 injured after an attack by a knife-wielding man at a facility for the disabled in Japan early on Tuesday, national broadcaster NHK reported. Police in Sagamihara, Kanagawa Prefecture, about 25 miles (40 km) southwest of Tokyo, have arrested Satoshi Uematsu, a 26-year old former employee at the facility, Japanese media reported. The 3-hectare (7.6 acres) facility, established by the local government and nestled on the wooded bank of the Sagami River, cares for people with a wide range of disabilities, NHK said, quoting an unidentified employee.
Up there: Netherlands, Latvia lead world for people's height
25 Jul 2016 at 4:06pm
NEW YORK (AP) ? If you want to see a tall population of men, go to the Netherlands. Tall women? Latvia.
Researchers publish U.S. data on police-related injuries
25 Jul 2016 at 3:38pm
By Will Boggs MD (Reuters Health) - An estimated 55,400 people were injured as a result of legal police interventions in the U.S. in 2012, a study found. ?On a typical day, three people die in this country and 150 are injured during incidents involving police,? Dr. Ted Miller from Pacific Institute for Research and Evaluation in Calverton, Maryland told Reuters Health by email. Miller and colleagues pooled information from several nationwide databases to estimate nonfatal injuries resulting from legal police interventions.
Human tests start on controversial Brazil cancer pill
25 Jul 2016 at 3:09pm
Human testing started Monday in Brazil on a controversial anti-cancer medicine that has been distributed in the country for years without having gone through proper trials. The drug, a synthetic phosphoethanolamine known widely as "the cancer pill," was beginning testing with 10 patients at the Sao Paulo Cancer Institute, the Sao Paulo state health department said. The pill was created by Sao Paulo University professor Gilberto Orivaldo Chierice in the 1990s.
Olympics unlikely to worsen global spread of Zika
25 Jul 2016 at 3:03pm
By Andrew M. Seaman (Reuters Health) - People visiting Brazil for the 2016 Olympics won't significantly add to the global spread of Zika virus, according to a new analysis. Most likely, only six to 80 people visiting Brazil for the Olympics would be infected with Zika virus, and between one and 16 would feel any symptoms, researchers suggest. The Olympic and Paralympic games, scheduled for August and September, are expected to bring 350,000 to 500,000 people to Brazil.
General Mills expands flour recall to more batches
25 Jul 2016 at 2:54pm
(Reuters) - General Mills Inc said it was expanding its flour recall to more batches after the detection of E. coli in its flour samples that led to four new cases of illnesses. One of the four persons developed a type of kidney failure, the Centers for Disease Control and Prevention said. (http://bit.ly/1sqaiw2) General Mills had recalled about 10 million pounds of flour in May and added two flavors of Betty Crocker cake mix in the United States and one in Canada to the recall in July. Monday's recall includes select production dates through Feb. 10. The previous recalls ranged from Nov. ...